- Home
- PHAR vs DXYZ Comparison
PHAR vs DXYZ Comparison
Compare PHAR & DXYZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- DXYZ
- Stock Information
- Founded
- PHAR 1988
- DXYZ N/A
- Country
- PHAR Netherlands
- DXYZ
- Employees
- PHAR N/A
- DXYZ N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- DXYZ
- Sector
- PHAR Health Care
- DXYZ
- Exchange
- PHAR Nasdaq
- DXYZ Nasdaq
- Market Cap
- PHAR 618.3M
- DXYZ 581.6M
- IPO Year
- PHAR N/A
- DXYZ 2024
- Fundamental
- Price
- PHAR $8.42
- DXYZ $52.35
- Analyst Decision
- PHAR Strong Buy
- DXYZ
- Analyst Count
- PHAR 3
- DXYZ 0
- Target Price
- PHAR $27.00
- DXYZ N/A
- AVG Volume (30 Days)
- PHAR 5.6K
- DXYZ N/A
- Earning Date
- PHAR 03-13-2025
- DXYZ N/A
- Dividend Yield
- PHAR N/A
- DXYZ N/A
- EPS Growth
- PHAR N/A
- DXYZ N/A
- EPS
- PHAR N/A
- DXYZ N/A
- Revenue
- PHAR $285,745,000.00
- DXYZ N/A
- Revenue This Year
- PHAR $20.08
- DXYZ N/A
- Revenue Next Year
- PHAR $9.22
- DXYZ N/A
- P/E Ratio
- PHAR N/A
- DXYZ N/A
- Revenue Growth
- PHAR 30.64
- DXYZ N/A
- 52 Week Low
- PHAR $6.65
- DXYZ N/A
- 52 Week High
- PHAR $13.20
- DXYZ N/A
- Technical
- Relative Strength Index (RSI)
- PHAR 40.05
- DXYZ N/A
- Support Level
- PHAR $7.95
- DXYZ N/A
- Resistance Level
- PHAR $9.35
- DXYZ N/A
- Average True Range (ATR)
- PHAR 0.52
- DXYZ 0.00
- MACD
- PHAR -0.16
- DXYZ 0.00
- Stochastic Oscillator
- PHAR 22.76
- DXYZ 0.00
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.